 acute leukemia Past experience future perspectives Etoposide single agent active relapsed refractory acute myelogenous leukemia AML complete responses CR rates drug cytarabine azacytidine vinca alkaloids anthracyclines remission rates patients AML experience etoposide acute lymphoblastic leukemia extensive drug active combination cytarabine aclacinomycin addition etoposide cytarabine anthracyclines primary treatment AML response rates comparable standard regimens Phase I/II trial efficacy NOVE combination days etoposide days patients refractory AML results extended duration etoposide administration CR rates Overall CR rate patients sequential regimen IDAC idarubicin/cytarabine NOVE primary treatment adult patients AML Cycles IDAC NOVE response results pilot study strategy patients CR Further studies way efficacy strategy